The review question was reasonably well-defined in terms of the participants, interventions, outcomes and study designs of interest. One electronic database plus other sources were searched for relevant evidence, although it was unclear whether the search was limited by language of publication. The authors did not mention any attempts to minimise the potential for errors or bias during the conduct of the review.
No attempt was made to assess the relative quality of included studies. It was not clear how the pooled outcomes were calculated.
Given these reporting limitations, it is not possible to determine the reliability of the authors' conclusions.
One of the authors disclosed financial links with several pharmaceutical companies, including Ipsen, the manufacturers of lanreotide (marketed as somatuline).